Targeting the dysregulated m6A regulators, which are overexpressed in tumor on most occasions, plentiful specific inhibitors have demonstrated exciting anti-tumor effects in vitro and in vivo (Table 6). This evidence concerns the gene METTL3 and neoplasm.